The parathyroid hormone market consists of sales of parathyroid hormones and related services by entities (organizations, sole traders and partnerships) that develop parathyroid hormones to treat various diseases. Parathyroid hormone is responsible for regulating the distribution of phosphate and calcium in the body and is used in the treatment of diseases such as hypothyroidism and osteoporosis.
The global parathyroid hormone market is expected to decline from $1.78 billion in 2019 to $1.70 billion in 2020 at a compound annual growth rate (CAGR) of -4.4%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $1.90 billion in 2023 at a CAGR of 3.9%.
